Biogen Acquires RayThera to Bolster Immunology Portfolio Amid Shifting Financial Dynamics
On August 6, Biogen (NASDAQ:BIIB) acquired RayThera, a biotech firm developing small-molecule immunology therapies. The acquisition follows the company's second-quarter earnings beat in July and reflects its strategy of pursuing external innovation to fuel growth beyond its aging multiple sclerosis business. Biogen’s recent financial performance shows mixed signals. While Leqembi, an Alzheimer’s drug developed with Eisai, saw a 15% year-over-year sales increase to $184 million, MS revenue declined by 13%. The company also raised its full-year revenue outlook but cut adjusted earnings guidance due to acquisition-related charges. The RayThera deal is part of Biogen’s broader strategy that includes the earlier $5.6 billion purchase of Apellis Pharmaceuticals in 2026, which expanded its presence into kidney disease and rare diseases.
Topics: Biogen Financial performance Immunology pipeline RayThera acquisition